Is Advaxis, Inc. (ADXS) a Buy, Sell, or Hold?
Advaxis, Inc.
PNK:ADXS
$0.027 USD
$0.08 (-152.84%)
- Volume
- 642
- Average Volume
- 829
- Market Capitalization
- $1.15M
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $1.49
- Year Low
- $0.00
- Payout Ratio
- $0.00
- Current Ratio
- $0.30
Industry, Sector & symbol
| Stock Exchange | Other OTC |
| CEO | Mr. Kenneth A. Berlin J.D. |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ADXS |
| CUSIP | 007624307 |
| CIK | 0001100397 |
| Web | https://www.advaxis.com |
| Phone | 609 452 9813 |
| Currency | USD |
| Employees | 20 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -0.34 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.30 |
| Quick Ratio | 0.30 |
| Cash Ratio | 0.20 |
Sales & Book Value
| Annual Sales | $13000 |
| Price / Sales | 127.90 |
| Cash Flow | -2.36 |
| Price / Cash Flow | -0.08 |
| Price / Book | -0.01 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-7.99 |
| Trailing P/E Ratio | 0.00 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-48.07M |
| Net Margin | -452344.44% |
| Pretax Margin | -449066.67% |
| Return on Equity | 411.93% |
| Return on Assets | -245.56% |
Financials Score
| AltmanZ Score | -25.14 |
| Piotroski Score | 1.00 |
| Working Capital | -17.49M |
| Total Assets | 16.58M |
| Ebit | -36.36M |
| Market Cap | 1.15M |
| Total Liabilities | 41M |
Poll Results
About Advaxis, Inc. (PNK:ADXS) Stock
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, ... LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
2024-05-09 16:10:00
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and to suspend its reporting obligations under Section 15(d) of the Exchange Act. The Company's obligation to file periodic reports with the SEC, including reports on Forms 10-K, 10-Q and 8-K, will be suspended immediately upon filing of the Form 15. Once the Form 15 is effective, which is expected to occur within 90 days of filing, the Company will no longer be a public reporting company and its obligations to file other reports with the SEC will also be suspended.
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
2024-03-26 08:00:00
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM).
2023-10-23 07:00:00
AL102 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population AL102 1.2 mg once daily treatment resulted in 88% reduction in tumor volume and 85% reduction in T2W signal intensity REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that new data from the RINGSIDE study evaluating its lead investigational candidate AL102 for the treatment of desmoid tumors (DT) are being presented today at the European Society for Molecular Oncology (ESMO) Congress 2023, taking place October 20th to 24th in Madrid, Spain.
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
2023-10-19 08:00:00
REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the closing of its merger with Biosight, Ltd. (“Biosight”), pursuant to which Ayala acquired Biosight. The combined company will operate under the name Ayala Pharmaceuticals, Inc., and its shares will continue to trade on the OTCQX under Ayala's current ticker symbol (“ADXS”).
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
2023-08-10 16:30:00
Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected to close near end of Q3 2023 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced second-quarter 2023 financial results and provided a corporate update.
Frequently Asked Questions
-
What is the current Advaxis, Inc. (ADXS) stock price?
-
Advaxis, Inc.(PNK:ADXS) stock price is $0.027 in the last trading session. During the trading session, ADXS stock reached the peak price of $1.49 while $0.0012 was the lowest point it dropped to. The percentage change in ADXS stock occurred in the recent session was -152.84% while the dollar amount for the price change in ADXS stock was $0.08.
-
ADXS's industry and sector of operation?
-
The PNK listed ADXS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ADXS?
-
Ms. Dana Gelbaum M.B.A., M.Sc. | GM & Chief Business Officer
Ms. Irit Klipper-Avni M.A. | Vice President of Human Resources
Mr. Kenneth A. Berlin J.D. | Chief Executive Officer, President & Director
|
| -
How many employees does ADXS have?
-
Number of ADXS employees currently stands at 20. ADXS operates from 9 Deer Park Drive, Monmouth Junction, NJ 08852, US.
-
Link for ADXS official website?
-
Official Website of ADXS is: https://www.advaxis.com
-
How do I contact ADXS?
-
ADXS could be contacted at phone #609 452 9813 and can also be accessed through its website. ADXS operates from 9 Deer Park Drive, Monmouth Junction, NJ 08852, US.
-
How many shares of ADXS are traded daily?
-
The average number of ADXS shares traded daily for last 3 months was 829.
-
What is the market cap of ADXS currently?
-
The market value of ADXS currently stands at $1.15M with its latest stock price at $0.027